Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Cardioprotection in Breast Cancer Patients Receiving Chemotherapy
NCT07883512Phase 2Not yet recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- Dec 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in heart failure (HF), sponsored by Virginia Commonwealth University. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT07883512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07883512.